Huafu Securities released a research report on April 24 stating that it gave Shengnuo Biotech (688117.SH) a purchase rating, and the target price was 35.7 yuan. The main reasons for the rating include: 1) GLP-1 is driving the expansion of the peptide market, and peptide APIs & CDMO are rising; 2) leading domestic peptide API companies, and production capacity construction continues to advance; 3) mastering core technology, the number of CDMO projects ranks among the highest in the country; 4) pharmaceutical business collection in exchange for price and volume, contributing to performance growth. (Mainichi Keizai Shimbun)
华福证券4月24日发布研报称，给予圣诺生物（688117.SH）买入评级，目标价格为35.7元。评级理由主要包括：1）GLP-1带动多肽市场扩容，多肽原料药&CDMO水涨船高；2）国内多肽原料药领头企业，产能建设持续推进；3）掌握核心技术，CDMO项目数量位居国内前列；4）制剂业务集采以价换量，贡献业绩增量。（每日经济新闻）
Huafu Securities released a research report on April 24 stating that it gave Shengnuo Biotech (688117.SH) a purchase rating, and the target price was 35.7 yuan. The main reasons for the rating include: 1) GLP-1 is driving the expansion of the peptide mark
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.